Vaccines & Biodefense

In the U.S., the recommended immunization series prevents approximately 33,000 deaths each year. Advancements in biotechnology have made it possible to produce vaccines that cannot transmit a virus or bacterium. This method has helped create more than 20 new vaccines against infectious agents, improved existing vaccines, and increased the amount of vaccine that can be produced.

Biotech Response to COVID-19

As the threat of the novel coronavirus continues to grow globally, innovative biopharmaceutical companies are ramping up efforts to study the virus and develop vaccines and cures to protect individuals from contracting the virus.

Blog Posts
September 16, 2020
In case you missed it, the Trump administration is moving forward with a plan to import into the United States dangerous government price setting for innovative cures and treatments. In a nutshell, the move will harm…
Biotech Leaders: Trust Science to Eradicate Covid-19
September 9, 2020
Biotech companies are working around the clock to develop safe and effective vaccines and treatments to combat and eradicate Covid-19. Thanks to this monumental push for innovation, there are well over 700 unique active…
August 12, 2020
During the last several months, biotech companies have heroically trained their resources and talent toward fighting the global COVID pandemic. The entire world recognizes that it is science that ultimately will help us…
Press Releases
June 16, 2020
The Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Executive Committee members for the 2020-2021 term. Additionally, eight new board directors and four new section governing board chairs and vice chairs were elected. BIO’s Board elections took place…
May 13, 2020
Following the announcement that Dr. Moncef Slaoui will lead the Trump Administration's "Operation Warp Speed" initiative, BIO’s President and CEO, Jim Greenwood, issued the following statement:  “Dr. Moncef Slaoui is an excellent choice to lead the President’s Operation Warp Speed…
May 12, 2020
The Biotechnology Innovation Organization (BIO) today unveiled a first-of-its-kind, interactive tracker of the new treatments and vaccines in the COVID-19 pipeline. This online resource illustrates the unprecedented campaign being undertaken by biopharmaceutical innovators to combat – and…
Letters, Comments & Testimony
July 31, 2020
July 31, 2020 Re: Docket No. FDA–2020-N-0837: Raare Disease Clinical Trial Network; Request for Information. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the opportunity to submit comments on the Request for…
July 30, 2020
July 30, 2020 Re: Docket No. FDA–2019-D-5799: FDA’s Public Meeting, Modernizing the Food and Drug Administration’s Data Strategy. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the opportunity to submit comments…
July 20, 2020
The following letter provides BIO’s feedback on a number of regulatory proposals by the Centers for Medicare & Medicaid Services that would ease barriers to use of value-based purchasing arrangements within Medicaid and commercial plans, broaden definitions of line extension, and place limits…
Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.